Overexpression of Notch3 and PS6 Is Associated with Poor Prognosis in Human Ovarian Epithelial Cancer

Overview

Journal Mediators Inflamm

Publisher Wiley

Specialties Biochemistry
Pathology

Date 2016 Jul 23

PMID 27445438

Citations 19

Authors

Zhaoxia Liu

Rongna Yun

Xiaolin Yu

Hui Hu

Genhua Huang

Buzhen Tan

Tingtao Chen

Affiliations

Soon will be listed here.

Abstract

Notch3 and pS6 play important roles in tumor angiogenesis. To assess the expression of Notch3 and pS6 in Chinese ovarian epithelial cancer patients, a ten-year follow-up study was performed in ovarian epithelial cancer tissues from 120 specimens of human ovarian epithelial cancer, 30 specimens from benign ovarian tumors, and 30 samples from healthy ovaries by immunohistochemistry. The results indicate that the expression of Notch3 and pS6 was higher in ovarian epithelial cancer than in normal ovary tissues and in benign ovarian tumor tissues (p < 0.01). In tumor tissues, Notch3 expression and pS6 expression were negatively associated with age (p > 0.05) but positively associated with clinical stage, pathological grading, histologic type, lymph node metastasis, and ascites (p < 0.05 or p < 0.01). A follow-up survey of 64 patients with ovarian epithelial cancer showed that patients with high Notch3 and pS6 expression had a shorter survival time (p < 0.01), in which the clinical stage (p < 0.05) and Notch3 expression (p < 0.01) played important roles. In conclusion, Notch3 and pS6 are significantly related to ovarian epithelial cancer development and prognosis, and their combination represents a potential biomarker and therapeutic target in ovarian tumor angiogenesis.

Citing Articles

Three-dimensional imaging of upper tract urothelial carcinoma improves diagnostic yield and accuracy.

Fukumoto K, Kanatani S, Jaremko G, West Z, Li Y, Takamatsu K JCI Insight. 2024; 9(14).

PMID: 39133649 PMC: 11383588. DOI: 10.1172/jci.insight.175751.

Disabled-2: a protein up-regulated by high molecular weight hyaluronan has both tumor promoting and tumor suppressor roles in ovarian cancer.

Price Z, Lokman N, Sugiyama M, Koya Y, Yoshihara M, Oehler M Cell Mol Life Sci. 2023; 80(11):320.

PMID: 37815603 PMC: 10564841. DOI: 10.1007/s00018-023-04972-9.

Expression of phosphorylated ribosomal protein S6 in mesothelioma patients - correlation with clinico-pathological characteristics and outcome: results from the European Thoracic Oncology Platform (ETOP) Mesoscape project.

Ruschoff J, Haberecker M, Tsourti Z, Nackaerts K, de Perrot M, Brcic L Mod Pathol. 2022; 35(12):1888-1899.

PMID: 36115922 PMC: 9708564. DOI: 10.1038/s41379-022-01145-0.

Weighted Correlation Network Analysis of Cancer Stem Cell-Related Prognostic Biomarkers in Esophageal Squamous Cell Carcinoma.

Zhao M, Jin X, Chen Z, Zhang H, Zhan C, Wang H Technol Cancer Res Treat. 2022; 21:15330338221117003.

PMID: 35899307 PMC: 9340319. DOI: 10.1177/15330338221117003.

Ribosomes and Ribosomal Proteins Promote Plasticity and Stemness Induction in Glioma Cells via Reprogramming.

Hide T, Shibahara I, Inukai M, Shigeeda R, Kumabe T Cells. 2022; 11(14).

PMID: 35883585 PMC: 9323835. DOI: 10.3390/cells11142142.

References

Yuan X, Wu H, Han N, Xu H, Chu Q, Yu S . Notch signaling and EMT in non-small cell lung cancer: biological significance and therapeutic application. J Hematol Oncol. 2014; 7:87. PMC: 4267749. DOI: 10.1186/s13045-014-0087-z. View

Wong A, Roskelley C, Pelech S, Miller D, Leung P, Auersperg N . Progressive changes in Met-dependent signaling in a human ovarian surface epithelial model of malignant transformation. Exp Cell Res. 2004; 299(1):248-56. DOI: 10.1016/j.yexcr.2004.06.002. View

Zhou H, Wong A . Activation of p70S6K induces expression of matrix metalloproteinase 9 associated with hepatocyte growth factor-mediated invasion in human ovarian cancer cells. Endocrinology. 2006; 147(5):2557-66. DOI: 10.1210/en.2005-1404. View

Hay N, Sonenberg N . Upstream and downstream of mTOR. Genes Dev. 2004; 18(16):1926-45. DOI: 10.1101/gad.1212704. View

Hopfer O, Zwahlen D, Fey M, Aebi S . The Notch pathway in ovarian carcinomas and adenomas. Br J Cancer. 2005; 93(6):709-18. PMC: 2361628. DOI: 10.1038/sj.bjc.6602719. View

Groeneweg J, Foster R, Growdon W, Verheijen R, Rueda B . Notch signaling in serous ovarian cancer. J Ovarian Res. 2014; 7:95. PMC: 4228063. DOI: 10.1186/s13048-014-0095-1. View

Ip C, Cheung A, Ngan H, Wong A . p70 S6 kinase in the control of actin cytoskeleton dynamics and directed migration of ovarian cancer cells. Oncogene. 2011; 30(21):2420-32. DOI: 10.1038/onc.2010.615. View

Artavanis-Tsakonas S, Rand M, Lake R . Notch signaling: cell fate control and signal integration in development. Science. 1999; 284(5415):770-6. DOI: 10.1126/science.284.5415.770. View

Bjornsti M, Houghton P . The TOR pathway: a target for cancer therapy. Nat Rev Cancer. 2004; 4(5):335-48. DOI: 10.1038/nrc1362. View

10.

Wang H, Huang X, Zhang J, Shao N, Chen L, Ma D . The expression of VEGF and Dll4/Notch pathway molecules in ovarian cancer. Clin Chim Acta. 2014; 436:243-8. DOI: 10.1016/j.cca.2014.06.005. View

11.

Jung J, Stoeck A, Guan B, Wu R, Zhu H, Blackshaw S . Notch3 interactome analysis identified WWP2 as a negative regulator of Notch3 signaling in ovarian cancer. PLoS Genet. 2014; 10(10):e1004751. PMC: 4214668. DOI: 10.1371/journal.pgen.1004751. View

12.

Palomero T, Sulis M, Cortina M, Real P, Barnes K, Ciofani M . Mutational loss of PTEN induces resistance to NOTCH1 inhibition in T-cell leukemia. Nat Med. 2007; 13(10):1203-10. PMC: 2600418. DOI: 10.1038/nm1636. View

13.

Ye Y, Zhang Z, Fan X, Xu X, Chen M, Chang B . Notch3 overexpression associates with poor prognosis in human non-small-cell lung cancer. Med Oncol. 2013; 30(2):595. DOI: 10.1007/s12032-013-0595-7. View

14.

Mirone G, Perna S, Shukla A, Marfe G . Involvement of Notch-1 in Resistance to Regorafenib in Colon Cancer Cells. J Cell Physiol. 2015; 231(5):1097-105. DOI: 10.1002/jcp.25206. View

15.

Pon Y, Zhou H, Cheung A, Ngan H, Wong A . p70 S6 kinase promotes epithelial to mesenchymal transition through snail induction in ovarian cancer cells. Cancer Res. 2008; 68(16):6524-32. DOI: 10.1158/0008-5472.CAN-07-6302. View

16.

Choi J, Park J, Davidson B, Morin P, Shih I, Wang T . Jagged-1 and Notch3 juxtacrine loop regulates ovarian tumor growth and adhesion. Cancer Res. 2008; 68(14):5716-23. PMC: 2562671. DOI: 10.1158/0008-5472.CAN-08-0001. View

17.

Egloff A, Grandis J . Molecular pathways: context-dependent approaches to Notch targeting as cancer therapy. Clin Cancer Res. 2012; 18(19):5188-95. PMC: 3463728. DOI: 10.1158/1078-0432.CCR-11-2258. View

18.

Cantley L . The phosphoinositide 3-kinase pathway. Science. 2002; 296(5573):1655-7. DOI: 10.1126/science.296.5573.1655. View

19.

Hu W, Liu T, Ivan C, Sun Y, Huang J, Mangala L . Notch3 pathway alterations in ovarian cancer. Cancer Res. 2014; 74(12):3282-93. PMC: 4058356. DOI: 10.1158/0008-5472.CAN-13-2066. View

20.

Yuan X, Wu H, Xu H, Xiong H, Chu Q, Yu S . Notch signaling: an emerging therapeutic target for cancer treatment. Cancer Lett. 2015; 369(1):20-7. DOI: 10.1016/j.canlet.2015.07.048. View